1. Wojas-Pelc A, Pastuszczak M, Jaworek A. Kiła. In: Wybrane choroby bakteryjne. Interna Szczeklika 2021. Szczeklik A, Gajewski P (ed.). Medycyna Praktyczna, Kraków 2021.
2.
Spiteri G, Unemo M, Mårdh O, Amato-Gauci AJ. The resurgence of syphilis in high-income countries in the 2000s: a focus on Europe. Epidemiol Infect 2019; 147: e143.
3.
Forrestel AK, Kovarik CL, Katz KA. Sexually acquired syphilis: historical aspects, microbiology, epidemiology, and clinical manifestations. J Am Acad Dermatol 2020; 82: 1-14.
4.
Pastuszczak M. Wybrane parametry aktywacji odpowiedzi komórkowej w kile, ze szczególnym uwzględnieniem kiły układu nerwowego (Doctoral dissertation, Wydział Lekarski), Uniwersytet Jagielloński Collegium Medicum, Kraków 2013.
5.
Tuddenham S, Ghanem KG. Management of adult syphilis: key questions to inform the 2021 centers for disease control and prevention sexually transmitted infections treatment guidelines. Clin Infect Dis 2022; 74 (Suppl 2): S127-33.
6.
Pastuszczak M. Czynniki warunkujące odpowiedź na leczenie kiły wczesnej, ze szczególnym uwzględnieniem zjawiska surowiczooporności, Uniwersytet Jagielloński Collegium Medicum w Krakowie 2019.
7.
Liu XK, Wang ZS, Li J. Predictors of serofast state after treatment of patients with syphilis. Chin Med J 2020; 133: 2874-6.
8.
World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact. 2021.
9.
Paul G, Wesselmann J, Adzic D, et al. Predictors of serofast state after treatment for early syphilis in HIV-infected patients. HIV Med 2021; 22: 165-71.
10.
Qin J, Yang T, Wang H, et al. Potential predictors for serofast state after treatment among HIV-negative persons with syphilis in China: a systematic review and meta-analysis. Iran J Public Health 2015; 44: 155-69.
11.
Seña AC, Wolff M, Martin DH, et al. Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis. Clin Infect Dis 2011; 53: 1092-9.
12.
Tong ML, Lin LR, Liu GL, et al. Factors associated with serological cure and the serofast state of HIV-negative patients with primary, secondary, latent, and tertiary syphilis. PLoS One 2013; 8: e70102.
13.
Li J, Wang LN, Zheng HY. Predictors of serological cure and serofast state after treatment in HIV-negative patients with early syphilis in China. Sex Transm Infect 2013; 89: 69.
14.
Leeyaphan C, Punyaratabandhu P, Jiamton S, et al. Predictors of serological cure after treatment in patients with early syphilis: a retrospective observational study in Thailand. Indian J Dermatol Venereol Leprol 2019; 85: 235.
15.
Dionne-Odom J, Karita E, Kilembe W, et al. Syphilis treatment response among HIV-discordant couples in Zambia and Rwanda. Clin Infect Dis 2013; 56: 1829-37.
16.
Pastuszczak M, Gozdzialska A, Jakiela B, et al. Robust pro-inflammatory immune response is associated with serological cure in patients with syphilis: an observational study. Sex Transm Infect 2017; 93: 11-4.
17.
Seña AC, Zhang XH, Li T, et al. A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect Dis 2015; 15: 479.
18.
Lin LR, Zheng WH, Tong ML, et al. Further evaluation of the characteristics of Treponema pallidum-specific IgM antibody in syphilis serofast reaction patients. Diagn Microbiol Infect Dis 2011; 71: 201-7.
19.
Pastuszczak M, Jakiela B, Wojas-Pelc A. Association of interleukin-10 promoter polymorphisms with serofast state after syphilis treatment. Sex Transm Infect 2019; 95: 163-8.
20.
Pastuszczak M, Kotnis-Gąska A, Jakubowicz B, Wojas-Pelc A. Treponema pallidum-specific immune responses and autoimmunity in patients who remain serofast after treatment of syphilis. Adv Dermatol Allergol 2019; 36: 620-5.
21.
Pastuszczak M, Jakiela B, Jaworek AK, et al. Association of Interleukin-10 promoter polymorphisms with neurosyphilis. Hum Immunol 2015; 76: 469-72.
22.
Marchese V, Tiecco G, Storti S, et al. Syphilis infections, reinfections and serological response in a large italian sexually transmitted disease centre: a monocentric retrospective study. J Clin Med 2022; 11: 7499.
23.
Pastuszczak M, Sitko M, Bociaga-Jasik M, et al. Lack of antiretroviral therapy is associated with higher risk of neurosyphilis among HIV-infected patients who remain serofast after therapy for early syphilis. Medicine 2018; 97: e13171.
24.
Kojima N, Siebert JC, Maecker H, et al. The application of cytokine expression assays to differentiate active from previously treated syphilis. J Infect Dis 2020; 222: 690-4.
25.
Kojima N, Siebert JC, Maecker H, et al. Cytokine expression in Treponema pallidum infection. J Transl Med 2019; 17: 196.
26.
Huang T, Zhang J, Ke W, et al. MicroRNA expression profiling of peripheral blood mononuclear cells associated with syphilis. BMC Infect Dis 2020; 20: 165.
27.
Huang T, Yang J, Zhang J, et al. MicroRNA-101-3p downregulates TLR2 expression, leading to reduction in cytokine production by Treponema pallidum-stimulated macrophages. J Invest Dermatol 2020; 140: 1566-75.e1.
28.
Dong X, Zhang J, Yang F, et al. CXCL8, CXCL9, and CXCL10 serum levels increase in syphilitic patients with seroresistance. J Clin Lab Anal 2021; 35: e24016.
29.
Seña AC, Wolff M, Behets F, et al. Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin. Clin Infect Dis 2013; 56: 420-2.
30.
Wang ZS, Liu XK, Li J. Serological response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin. J Antimicrob Chemother 2018; 73: 1348-51.
31.
Cai SN, Long J, Chen C, et al. Incidence of asymptomatic neurosyphilis in serofast Chinese syphilis patients. Sci Rep 2017; 7: 15456.
32.
Weng W, Hou J, Song B, et al. Identification of the factors associated with post-treatment asymptomatic neurosyphilis in HIV-negative patients with serological non-response syphilis: a retrospective study. Int J STD AIDS 2021; 32: 331-5.
33.
Tan X, Zhang J, Li J, et al. The prevalence of asymptomatic neurosyphilis among HIV-negative serofast patients in China: a meta-analysis. PLoS One 2020; 15: e0241572.
34.
Workowski KA, Berman SM. Centers for Disease Control and Prevention Sexually Transmitted Disease treatment guidelines. Clin Infect Dis 2011; 53 Suppl 3: S59-63.
35.
Workowski KA. Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment guidelines. Clin Infect Dis 2015; 61 Suppl 8: S759-62.
36.
Workowski KA, Bachmann LH. Centers for Disease Control and Prevention’s Sexually Transmitted Diseases Infection guidelines. Clin Infect Dis 2022; 74 (Suppl 2): S89-94.
37.
Kotlarz A. Odpowiedź serologiczna na leczenie kiły wczesnej u kobiet w ciąży (Doctoral dissertation). Wydział Nauk o Zdrowiu), Uniwersytet Jagielloński Collegium Medicum, Krakow 2022.
38.
Rac MW, Revell PA, Eppes CS. Syphilis during pregnancy: a preventable threat to maternal-fetal health. Am J Obstet Gynecol 2017; 216: 352-63.
39.
Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70: 1-187.
40.
Lorenz ZW, Nijhar S, Caufield-Noll C, et al. The utility of biomarkers in the clinical management of syphilis: a systematic review. Sex Transm Dis 2023; 50: 472-8.
